• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Xyzal (levocetirizine dihydrochloride) oral solution and tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) 

 

 

November 2013

Summary View

ADVERSE REACTIONS

Post-Marketing Experience
  • movement disorders (including dystonia and oculogyric crisis
  • tic, myoclonus, extrapyramidal symptoms

 

September 2012

Summary View

5 WARNINGS AND PRECAUTIONS

5.2 Urinary Retention
  • Urinary retention has been reported post-marketing....

6 ADVERSE REACTIONS

6.2 Postmarketing Experience
  • added ..... urinary retention

17 PATIENT COUNSELING INFORMATION

 

 

March 2011 

Summary View

 

ADVERSE REACTIONS

 Postmarketing Experience
  • vomiting, dysuria, blurred vision, angioedema, paraesthesia, dizziness